IDEAS home Printed from https://ideas.repec.org/b/wbk/wbpubs/15231.html
   My bibliography  Save this book

The Indian Pharmaceutical Sector : Issues and Options for Health Sector Reform

Author

Listed:
  • Ramesh Govindaraj
  • Gnanaraj Chellaraj

Abstract

This report assesses the pharmaceutical sector in India, particularly focusing on four key issues related to the production, procurement, and distribution of drugs in India: a) availability, b) affordability; c) quality, and d) the rational use of drugs. The results of a survey of three states indicate considerable variation across states in the above four areas in both public and private sectors. The report concludes that problems with the availability, affordability, and rational use of good quality, cost-effective, essential drugs have persisted in most parts of India, and that these health-related issues need be addressed as a priority. An overarching recommendation is the need to focus on strengthening the implementation and regulation of the pharmaceutical sector at the state level, rather than on simply introducing new regulations. Adequate pharmaceutical quality assurance needs to be particularly emphasized as, in its absence, other reform measures could be rendered moot. Similarly, the rational use of drugs needs to be emphasized as it is likely to yield significant cost savings to the government and to consumers, in addition to its positive impact on health.

Suggested Citation

  • Ramesh Govindaraj & Gnanaraj Chellaraj, 2002. "The Indian Pharmaceutical Sector : Issues and Options for Health Sector Reform," World Bank Publications - Books, The World Bank Group, number 15231, December.
  • Handle: RePEc:wbk:wbpubs:15231
    as

    Download full text from publisher

    File URL: https://openknowledge.worldbank.org/bitstream/handle/10986/15231/multi0page.pdf?sequence=1
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Okumura, Junko & Wakai, Susumu & Umenai, Takusei, 2002. "Drug utilisation and self-medication in rural communities in Vietnam," Social Science & Medicine, Elsevier, vol. 54(12), pages 1875-1886, June.
    2. Gordon C. Rausser & Arthur A. Small, 2000. "Valuing Research Leads: Bioprospecting and the Conservation of Genetic Resources," Journal of Political Economy, University of Chicago Press, vol. 108(1), pages 173-206, February.
    3. Sean Nicholson, 2005. "Biotech-Pharmaceutical Alliances as a Signal of Asset and Firm Quality," The Journal of Business, University of Chicago Press, vol. 78(4), pages 1433-1464, July.
    4. Gorina-Ysern, Montserrat, 0. "Marine scientific research activities as the legal basis for intellectual property claims?," Marine Policy, Elsevier, vol. 22(4-5), pages 337-357, July.
    5. Sedjo, Roger A, 1992. "Property Rights, Genetic Resources, and Biotechnological Change," Journal of Law and Economics, University of Chicago Press, vol. 35(1), pages 199-213, April.
    6. Sumner J. La Croix & Denise Eby Konan, 2002. "Intellectual Property Rights in China: The Changing Political Economy of Chinese–American Interests," The World Economy, Wiley Blackwell, vol. 25(6), pages 759-788, June.
    7. James R. Markusen, 2021. "Contracts, intellectual property rights, and multinational investment in developing countries," World Scientific Book Chapters, in: BROADENING TRADE THEORY Incorporating Market Realities into Traditional Models, chapter 8, pages 159-174, World Scientific Publishing Co. Pte. Ltd..
    8. Simpson, R David & Sedjo, Roger A & Reid, John W, 1996. "Valuing Biodiversity for Use in Pharmaceutical Research," Journal of Political Economy, University of Chicago Press, vol. 104(1), pages 163-185, February.
    9. Felker, G. & Chaudhuri, S. & Gyorgy, K. & Goldman, M., 1997. "The Pharmaceutical Industry in India and Hungary. Policies, Institutions, and Technological Development," Papers 392, World Bank - Technical Papers.
    10. Swanson, Timothy & Goschl, Timo, 2000. "Property rights issues involving plant genetic resources: implications of ownership for economic efficiency," Ecological Economics, Elsevier, vol. 32(1), pages 75-92, January.
    11. Lall, Sanjaya, 1974. "The International Pharmaceutical Industry and Less-Developed Countries, with Special Reference to India," Oxford Bulletin of Economics and Statistics, Department of Economics, University of Oxford, vol. 36(3), pages 143-172, August.
    12. Maskus, Keith E, 1998. "Strengthening Intellectual Property Rights in Asia: Implications for Australia," Australian Economic Papers, Wiley Blackwell, vol. 37(3), pages 346-361, September.
    13. Mazzoleni, Roberto & Nelson, Richard R., 1998. "The benefits and costs of strong patent protection: a contribution to the current debate," Research Policy, Elsevier, vol. 27(3), pages 273-284, July.
    14. Mattias Ganslandt & Keith E. Maskus & Eina V. Wong, 2001. "Developing and Distributing Essential Medicines to Poor Countries: The DEFEND Proposal," The World Economy, Wiley Blackwell, vol. 24(6), pages 779-795, June.
    15. Homedes, Nuria & Ugalde, Antonio, 2001. "Improving the use of pharmaceuticals through patient and community level interventions," Social Science & Medicine, Elsevier, vol. 52(1), pages 99-134, January.
    16. Kirim, Arman S., 1986. "Transnational corporations and local capital: Comparative conduct and performance in the Turkish pharmaceutical industry," World Development, Elsevier, vol. 14(4), pages 503-521, April.
    17. D. Schartinger & C. Rammer & J. Fröhlich, 2006. "Knowledge Interactions between Universities and Industry in Austria: Sectoral Patterns and Determinants," Springer Books, in: Innovation, Networks, and Knowledge Spillovers, chapter 7, pages 135-166, Springer.
    18. Kirim, Arman S., 1985. "Reconsidering patents and economic development: A case study of the Turkish pharmaceutical industry," World Development, Elsevier, vol. 13(2), pages 219-236, February.
    19. Catherine Matraves, 1999. "Market Structure, R&D and Advertising in the Pharmaceutical Industry," Journal of Industrial Economics, Wiley Blackwell, vol. 47(2), pages 169-194, June.
    20. Sikka, Pawan, 1998. "Analysis of in-house R&D centres of innovative firms in India," Research Policy, Elsevier, vol. 27(4), pages 429-433, August.
    21. Katrak, Homi, 1998. "Economic analyses of Industrial Research Institutes in developing countries: the Indian experience," Research Policy, Elsevier, vol. 27(4), pages 337-347, August.
    22. Fink, Carsten, 2000. "How stronger patent protection in India might affect the behavior of transnational pharaceutical industries," Policy Research Working Paper Series 2352, The World Bank.
    23. Keith E. Maskus & Mohamed Lahouel, 2000. "Competition Policy and Intellectual Property Rights in Developing Countries," The World Economy, Wiley Blackwell, vol. 23(04), pages 595-611, April.
    24. White, Steven & Liu, Xielin, 1998. "Organizational processes to meet new performance criteria: Chinese pharmaceutical firms in transition," Research Policy, Elsevier, vol. 27(4), pages 369-383, August.
    25. Keith Maskus, 1998. "Strengthening Intellectual Property Rights in Asia: Implications for Australia," Australian Economic Papers, Wiley Blackwell, vol. 37(3), pages 346-361, September.
    26. repec:hhs:iuiwop:552 is not listed on IDEAS
    27. Ramani, Shyama V., 2002. "Who is interested in biotech? R&D strategies, knowledge base and market sales of Indian biopharmaceutical firms," Research Policy, Elsevier, vol. 31(3), pages 381-398, March.
    28. Holloway, Kathleen A. & Gautam, Bharat R. & Harpham, Trudy & Taket, Ann, 2002. "The influence of user fees and patient demand on prescribers in rural Nepal," Social Science & Medicine, Elsevier, vol. 54(6), pages 905-918, March.
    29. Tapon, Francis & Cadsby, Charles Bram, 1996. "The optimal organization of research: evidence from eight case studies of pharmaceutical firms," Journal of Economic Behavior & Organization, Elsevier, vol. 31(3), pages 381-399, December.
    30. Erik Canton & Ed Westerhout, 1999. "A model for the Dutch pharmaceutical market," Health Economics, John Wiley & Sons, Ltd., vol. 8(5), pages 391-402, August.
    31. Gothoskar, S. S., 1983. "Drug control: India," World Development, Elsevier, vol. 11(3), pages 223-228, March.
    32. Stenson, Bo & Syhakhang, Lamphone & Eriksson, Bo & Tomson, Göran, 2001. "Real world pharmacy: assessing the quality of private pharmacy practice in the Lao People's Democratic Republic," Social Science & Medicine, Elsevier, vol. 52(3), pages 393-404, February.
    33. Lanjouw, Jean O. & Cockburn, Iain M., 2001. "New Pills for Poor People? Empirical Evidence after GATT," World Development, Elsevier, vol. 29(2), pages 265-289, February.
    34. Matraves, Catherine, 1999. "Market Structure, R&D and Advertising in the Pharmaceutical Industry," Journal of Industrial Economics, Wiley Blackwell, vol. 47(2), pages 169-194, June.
    35. Sharma, Suneeta & Hotchkiss, David R., 2001. "Developing financial autonomy in public hospitals in India: Rajasthan's model," Health Policy, Elsevier, vol. 55(1), pages 1-18, January.
    36. Jayashree Watal, 2000. "Pharmaceutical Patents, Prices and Welfare Losses: Policy Options for India Under the WTO TRIPS Agreement," The World Economy, Wiley Blackwell, vol. 23(5), pages 733-752, May.
    37. Artuso, Anthony, 2002. "Bioprospecting, Benefit Sharing, and Biotechnological Capacity Building," World Development, Elsevier, vol. 30(8), pages 1355-1368, August.
    38. Edward Barbier & Bruce Aylward, 1996. "Capturing the pharmaceutical value of biodiversity in a developing country," Environmental & Resource Economics, Springer;European Association of Environmental and Resource Economists, vol. 8(2), pages 157-181, September.
    39. Susan Walcott, 2001. "Growing Global: Learning Locations in the Life Sciences," Growth and Change, Wiley Blackwell, vol. 32(4), pages 511-532.
    40. Amy Craft & R. Simpson, 2001. "The Value of Biodiversity in Pharmaceutical Research with Differentiated Products," Environmental & Resource Economics, Springer;European Association of Environmental and Resource Economists, vol. 18(1), pages 1-17, January.
    41. Henry Grabowski & John Vernon, 2000. "The determinants of pharmaceutical research and development expenditures," Journal of Evolutionary Economics, Springer, vol. 10(1), pages 201-215.
    42. Feller, Irwin & Ailes, Catherine P. & Roessner, J. David, 2002. "Impacts of research universities on technological innovation in industry: evidence from engineering research centers," Research Policy, Elsevier, vol. 31(3), pages 457-474, March.
    43. Keith E. Maskus, 2000. "Intellectual Property Rights in the Global Economy," Peterson Institute Press: All Books, Peterson Institute for International Economics, number 99, October.
    44. Basberg, Bjorn L., 1983. "Foreign patenting in the U.S. as a technology indicator : The case of Norway," Research Policy, Elsevier, vol. 12(4), pages 227-237, August.
    45. Wionczek, Miguel S., 1983. "Research and development in pharmaceuticals: Mexico," World Development, Elsevier, vol. 11(3), pages 243-250, March.
    46. Sadequl Islam, 2001. "Concentration of international trade in high-technology products," Applied Economics Letters, Taylor & Francis Journals, vol. 8(2), pages 95-97.
    47. Keith E. Maskus & Mohamed Lahouel, 2000. "Competition Policy and Intellectual Property Rights in Developing Countries," The World Economy, Wiley Blackwell, vol. 23(4), pages 595-611, April.
    48. Paul Romer, 2002. "When Should We Use Intellectual Property Rights?," American Economic Review, American Economic Association, vol. 92(2), pages 213-216, May.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Jean O. Lanjouw, 2005. "Patents, Price Controls, and Access to New Drugs: How Policy Affects Global Market Entry," NBER Working Papers 11321, National Bureau of Economic Research, Inc.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Panle Jia & Pinelopi K. Goldberg & Shubham Chaudhuri, 2006. "Estimating the Effects of Global Patent Protection in Pharmaceuticals: A Case Study of Quinolones in India," American Economic Review, American Economic Association, vol. 96(5), pages 1477-1514, December.
    2. Papageorgiadis, Nikolaos & Cross, Adam R. & Alexiou, Constantinos, 2013. "The impact of the institution of patent protection and enforcement on entry mode strategy: A panel data investigation of U.S. firms," International Business Review, Elsevier, vol. 22(1), pages 278-292.
    3. Wenjuan Cheng & Alessio D’Amato & Giacomo Pallante, 2020. "Benefit sharing mechanisms for agricultural genetic diversity use and on-farm conservation," Economia Politica: Journal of Analytical and Institutional Economics, Springer;Fondazione Edison, vol. 37(1), pages 337-355, April.
    4. Padmashree Gehl Sampath, 2010. "Economic Aspects of Access to Medicines after 2005: Product Patent Protection and Emerging Firm Strategies in the Indian Pharmaceutical Industry," Working Papers id:3336, eSocialSciences.
    5. Patricia M. Danzon & Eric L. Keuffel, 2014. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484, National Bureau of Economic Research, Inc.
    6. Kassar, Ilhem & Lasserre, Pierre, 2004. "Species preservation and biodiversity value: a real options approach," Journal of Environmental Economics and Management, Elsevier, vol. 48(2), pages 857-879, September.
    7. Baumgartner, Stefan & Becker, Christian & Faber, Malte & Manstetten, Reiner, 2006. "Relative and absolute scarcity of nature. Assessing the roles of economics and ecology for biodiversity conservation," Ecological Economics, Elsevier, vol. 59(4), pages 487-498, October.
    8. Shilpi Tyagi & D. K. Nauriyal & Rachita Gulati, 2018. "Firm level R&D intensity: evidence from Indian drugs and pharmaceutical industry," Review of Managerial Science, Springer, vol. 12(1), pages 167-202, January.
    9. Dedeurwaerdere, Tom & Krishna, Vijesh V. & Pascual, Unai, 2005. "Biodiscovery And Intellectual Property Rights: A Dynamic Approach To Economic Efficiency," Environmental Economy and Policy Research Discussion Papers 31928, University of Cambridge, Department of Land Economy.
    10. Christine Greenhalgh & Padraig Dixon, 2002. "The Economics of Intellectual Property: A Review to Identify Themes for Future Research," Economics Series Working Papers 135, University of Oxford, Department of Economics.
    11. Artuso, Anthony, 2002. "Bioprospecting, Benefit Sharing, and Biotechnological Capacity Building," World Development, Elsevier, vol. 30(8), pages 1355-1368, August.
    12. Charles Palmer & Salvatore Di Falco, 2012. "Biodiversity, poverty, and development," Oxford Review of Economic Policy, Oxford University Press and Oxford Review of Economic Policy Limited, vol. 28(1), pages 48-68, Spring.
    13. Wright, Brian D. & Pardey, Philip G. & Nottenburg, Carol & Koo, Bonwoo, 2007. "Agricultural Innovation: Investments and Incentives," Handbook of Agricultural Economics, in: Robert Evenson & Prabhu Pingali (ed.), Handbook of Agricultural Economics, edition 1, volume 3, chapter 48, pages 2533-2603, Elsevier.
    14. Ding, Helen & Nunes, Paulo A.L.D. & Onofri, Laura, 2007. "An Economic Model for Bioprospecting Contracts," Sustainability Indicators and Environmental Valuation Working Papers 7450, Fondazione Eni Enrico Mattei (FEEM).
    15. Maria Pluvia ZUNIGA & Emmanuel COMBE, 2002. "Introducing Patent Protection In The Pharmaceutical Sector:," Region et Developpement, Region et Developpement, LEAD, Universite du Sud - Toulon Var, vol. 16, pages 191-221.
    16. Amy Craft & R. Simpson, 2001. "The Value of Biodiversity in Pharmaceutical Research with Differentiated Products," Environmental & Resource Economics, Springer;European Association of Environmental and Resource Economists, vol. 18(1), pages 1-17, January.
    17. Dolfsma, W.A., 2006. "IPRs, Technological Development, and Economic Development," ERIM Report Series Research in Management ERS-2006-004-ORG, Erasmus Research Institute of Management (ERIM), ERIM is the joint research institute of the Rotterdam School of Management, Erasmus University and the Erasmus School of Economics (ESE) at Erasmus University Rotterdam.
    18. Bond, Eric W. & Saggi, Kamal, 2014. "Compulsory licensing, price controls, and access to patented foreign products," Journal of Development Economics, Elsevier, vol. 109(C), pages 217-228.
    19. Gianluca Baio & Laura Magazzini & Antonio Nicita & Fabio Pammolli & Massimo Riccaboni, 2003. "Il Decreto DL 15/04/2002, n. 63 sul Contenimento della Spesa Farmaceutica - Impatto sull'Industria e Distorsioni nel Funzionamento del Mercato," Working Papers CERM 0-2003, Competitività, Regole, Mercati (CERM).
    20. Ming Liu & Sumner LaCroix, 2011. "The Impact of Stronger Property Rights in Pharmaceuticals on Innovation in Developed and Developing Countries," Working Papers 201116, University of Hawaii at Manoa, Department of Economics.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:wbk:wbpubs:15231. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Tal Ayalon (email available below). General contact details of provider: https://edirc.repec.org/data/dvewbus.html .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.